DRUG logo

BRIGHT MINDS BIOSCIENCES INC

DRUGNASDAQ
US Equity
$278.65▼ $22.24 (−7.98%)
Simulated price
🔔
Track DRUG
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 8.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$433.30B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good
No chart data available for DRUG.

Trading Snapshot

Day Range
$277.02 – $281.62
52-Week Range
—
Volume
$5.20B
Avg Volume
$4.80B
Shares Outstanding
9.8M
Next Earnings
Oct 20, 2026

Fundamentals Snapshot

Annual Revenue
$54.85B
Last Q Revenue
$12.74B
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+66.9%

Why Investors Own DRUG

  • ✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DRUG logo

BRIGHT MINDS BIOSCIENCES INC

DRUG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$14M▲ +393.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +369.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.8M▲ +66.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$89M▲ +$31M YoY
StockOtter · stockotter.space

About BRIGHT MINDS BIOSCIENCES INC

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$359.94
▲ +29.2% Upside
High Target$401.41
Low Target$307.10
Based on 31 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

BRIGHT MINDS BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift DRUG price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

BRIGHT MINDS BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.